Patrys expands pipeline with oncology antibody acquistion
This article was originally published in Scrip
Executive Summary
The Australian biotech company Patrys, which specialises in natural human antibody therapies, has upgraded its product pipeline from preclinical to clinical with the acquisition of the gastric cancer antibody product SC1 from Debiopharm's subsidiary Debiovision.